|
||
|
|
|
") //--> |
Latest | 1 | 2 | 3 | 4 | 5 | 6 |7 | Index | |||
Seattle Researchers Again Seek African-American Families For Prostate Cancer Genetic Study PSA level predicts future prostate growth in benign disease (BPH) Patients need better idea of when they will die, doctors say
Doctors who refer terminally ill patients to hospice care are consistently overoptimistic, according to a study by University of Chicago researchers Elizabeth Lamont and Nicholas Christakis published February 19, 2000. Typically, doctors predicted that their dying patients (including prostate cancer patients) would live 5 times longer after entering hospice than they actually did. This made death seem unexpected and sudden. The patient and the family lost out on choices and control.Full story PDEF, a novel genetic factor, may be involved in making prostate cancer hormone refractory Treat depression in the dying, American College of Physicians Panel Urges February 1, 2000. Dying patients are often depressed, yet depression - even normal grieving - often goes unrecognized by the patient, family or the physician, according to an End-of-Leife Care Panel set up by the American College of Physicians and American Society of Internal Medicine. In a new paper, the panel shows physicians how to identify and heal depression in the terminally ill patient and encourages them to do so. You can read the full paper on line and link to resources forpatients and caregivers. Full story Non-toxic peptide blocks spread of prostate cancer in rats, U-M scientists claim Jan 25, 2000. ANN ARBOR, Mich. /PSA Rising/ --University of Michigan scientists say that they have developed a new cancer-inhibiting peptide that has proven to be effective at preventing metastatic prostate cancer from spreading to other organs in rats. Dosed with this peptide, rats developed smaller primary tumors and fewer lung metastases than untreated rats and showed no toxic side effects from the treatment. If future studies show the peptide works as well in people, the researchers say, it could be the basis for a new approach to cancer therapy. Full story Copper-Lowering Drug Stabilizes Cancer By depriving cancer tumors of the copper supply they need to form new blood vessels, University of Michigan researchers report they have stopped the growth and spread of the disease in a small group of patients with cancer including prostate cancer. Full story Sexual and Urinary Complications After Radical Prostate Surgery |
|||
Drug relieves severe constipation from painkillers used for advanced cancer Jan 18, 2000. Methylnaltrexone, a drug designed to relieve constipation caused by opium-based pain killers without interfering with pain relief, is rapidly effective at low doses with no apparent side effects, report researchers from the University of Chicago, who are trying now to market the drug. Full story |
|||
Duke Study Uncovers Microscopic Interaction of Cancer Cells and Blood Vessels
January 18, 2000.
|
|||
Canstatin, Anti-Angiogenisis Agent, Tested on Prostate Cancer In Mice January 6, 2000. Researchers in Boston have found a substance that thwarts tumor growth
by blocking formation and growth of new blood vessels. Used on mice, the new protein, named "canstatin," is as effective as twice the dose of the well-known angiogenic inhibitor endostatin. In mice models of renal cancer, canstatin
stopped growth or slightly shrank tumors to as much as one-fourth the
size of tumors in mice treated with a dummy drug.. The paper is published in the
Jan. 14 issue of the Journal of Biological Chemistry (published online Jan. 7 at
www.jbc.org). Full story |
|||
Men Choosing Prostate Surgery Need Expert Uros, Otherwise Risk Impotence and Incontinence Jan 5, 2000. Many men with prostate cancer may endanger their lives by avoiding prostate removal, unwilling to deal with the surgery's reported side effects. But a Johns Hopkins study says that patients treated by an expert surgeon with a lot of experience are far more likely to remain continent and potent than those whose operations were done by a less experienced doctor. This study's potency and continency rates are the highest ever reported after prostate removal. Full story |
|||
For Biopsy, Get Second Pathologist's Opinion Or Risk Wrong Diagnosis Dec 13, 1999. A study of more than 6,000 patients by Johns Hopkins researchers found that one or two out of every 100 people who come to larger medical centers for treatment following a biopsy arrive with a diagnosis that's "totally wrong." The results suggest that second opinion pathology exams not only prevent errors, but also save lives and money. Full story |
|||
Immediate Hormonal Therapy for Men with Node Micro Metastases Improves Survival Immediate antiandrogen therapy after radical prostatectomy and pelvic lymphadenectomy improves survival and reduces the risk of recurrence in patients with node-positive prostate cancer, a new study int he New England Journal of Medicine says. An editorial by Patrick Walsh M.D. questioning the findings aappears in the same issue. We have links to both. Full story Hormones Improve Odds in Higher Risk Radiation Therapy, Study Says Patients taking radiation therapy for large tumors confined to the prostate get more benefit if they take hormone treatment before, during and after radiation treatments, according to a Fox-Chase researcher who presented at the American Society for Therapeutic Radiology annual meeting in San Antonio. We look at the statistics of failure nationwide and offer links to abstracts of recent overviews and studies of the effects of adding hormones to standard therapies. Full story |
|||
|
|||
|
prostate cancer activist news http://www.psa-rising.com ©1997-2000 |